ELSEVIER

Blood 142 (2023) 2619

The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

322.DISORDERS OF COAGULATION OR FIBRINOLYSIS: CLINICAL AND EPIDEMIOLOGICAL

Serpin-PC in Persons with Severe Hemophilia (PwH): Updated Results from a Multicenter Multi-Part, First-in-Human Study

Trevor Baglin[1], *James A. Huntington, PhD*[2], *Annelize Koch, MD*[3], *Irina Mocanu, MD*[4], *Levani Makhaldiani, MD*[5]

[1] ApcinteX Ltd (a subsidiary of Centessa Pharmaceuticals plc), Boston, MA
[2] Cambridge Institute for Medical Research University of Cambridge, Cambridge, GBR
[3] Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, United Kingdom
[4] Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Moldova, The Republic of
[5] Arensia Exploratory Medicine, Tbilisi, Georgia

Introduction
SerpinPC is an investigational serine protease inhibitor (SERPIN) engineered to specifically inhibit Activated Protein C (APC). The previously presented data from the completed parts of AP-0101 showed that administration of SerpinPC reduced bleeding in persons with severe hemophilia with no observations of unexplained chronic elevation in D-dimer. We will now present all results up to the end of Part 5 by which time we anticipate the median continuous exposure will be more than 3 years.

Methods
AP-0101 is an ongoing first-in-human open-label multicenter study utilizing an adaptive design to investigate the safety, tolerability, pharmacokinetics and efficacy of SerpinPC in subjects with severe hemophilia A and B.
Part 1a was a Single Ascending Dose Study of SerpinPC in 15 healthy male volunteers and 12 males with severe hemophilia.
Part 2 enrolled 23 males with severe hemophilia (19 hemophilia A and 4 hemophilia B), who were not on replacement factor prophylaxis, to receive SerpinPC at 0.3, 0.6 or 1.2 mg/kg, administered as a subcutaneous (SC) injection once every 4 weeks over a 24-week period (6 total doses).
In Part 3, subjects who completed Part 2 received a flat dose of 60 mg of SerpinPC once every 4 weeks for 48 weeks.
Part 4 was a further extension in which subjects who completed Part 3 received 1.2 mg/kg of SerpinPC once every 2 weeks for 24 weeks.
Part 5 was a further extension in which subjects who completed Part 4 continued to receive 1.2 mg/kg of SerpinPC once every 2 weeks for 52 weeks.

Results
Annualized bleed rates, safety and tolerability for Part 5 will be available and a complete summary of all results to the end of Part 5 will be presented, including available pharmacokinetic and anti-drug antibody data.

Disclosures Baglin: *Centessa Pharmaceuticals Plc:* Current Employment, Current equity holder in publicly-traded company, Current holder of *stock options* in a privately-held company. **Huntington:** *Centessa Pharmaceuticals Plc:* Consultancy, Current equity holder in publicly-traded company, Ended employment in the past 24 months.

https://doi.org/10.1182/blood-2023-179969